Endotheline bei kardiovaskulären Erkrankungen (Endothelins in cardiovascular disease)

Kähler, Jan; Köster, Ralf; Paul, M H; Hamm, Carlo; Meinertz, Thomas

doi:10.1007/s003920050073

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A longer isoform, SRTX-m of 24 amino acids with three additional C-terminal residues, has, however, been isolated from the venom of Atractaspis microlepidota microlepidota and shows high sequence homology to SRTX-b [193]. SRTXs are potent vasoconstrictor peptides with approximately 60% sequence homology and functional identity to the mammalian vasoconstrictor hormones endothelins [194,195]. Several isoforms of SRTXs can coexist within the same venom with different effects, such as SRTX-a, -b, and -c that are all purified from the snake venom Atractaspis engaddensis and that present different vasoactive effects linked to their primary structure [196].…”

Section: Sarafotoxinsmentioning

confidence: 99%

Snake Venom Components as Therapeutic Drugs in Ischemic Heart Disease

Messadi

2023

Biomolecules

View full text Add to dashboard Cite

Ischemic heart disease (IHD), especially myocardial infarction (MI), is a leading cause of death worldwide. Although coronary reperfusion is the most straightforward treatment for limiting the MI size, it has nevertheless been shown to exacerbate ischemic myocardial injury. Therefore, identifying and developing therapeutic strategies to treat IHD is a major medical challenge. Snake venoms contain biologically active proteins and peptides that are of major interest for pharmacological applications in the cardiovascular system (CVS). This has led to their use for the development and design of new drugs, such as the first-in-class angiotensin-converting enzyme inhibitor captopril, developed from a peptide present in Bothrops jararaca snake venom. This review discusses the potential usefulness of snake venom toxins for developing effective treatments against IHD and related diseases such as hypertension and atherosclerosis. It describes their biological effects at the molecular scale, their mechanisms of action according to their different pharmacological properties, as well as their subsequent molecular pathways and therapeutic targets. The molecules reported here have either been approved for human medical use and are currently available on the drug market or are still in the clinical or preclinical developmental stages. The information summarized here may be useful in providing insights into the development of future snake venom-derived drugs.

show abstract

Section: Sarafotoxinsmentioning

confidence: 99%

Snake Venom Components as Therapeutic Drugs in Ischemic Heart Disease

Messadi

2023

Biomolecules

View full text Add to dashboard Cite

show abstract

Coronary Artery Disease and Endothelial Function

Schächinger¹,

Zeiher²

2002

Pan Vascular Medicine

View full text Add to dashboard Cite

Therapeutische Optionen zur Verbesserung der Myokardperfusion bei koronarer Atherosklerose

Schächinger

1998

Herz

View full text Add to dashboard Cite

The combination of morphological atherosclerotic alterations of coronary vessels and disturbance of coronary vasomotor control of epicardial and resistance vessels determines the amount of myocardial oxygen supply. The endothelium plays a crucial role for functional alterations of the coronary vessels in patients with early atherosclerosis or risk factors for coronary artery disease. A therapy which aims to ameliorate endothelium-dependent vasodilator capacity improves myocardial perfusion in patients with coronary artery disease. Thereby, even in patients with angiographically normal or minimally diseased coronary vessels who develop myocardial ischemia due to microvascular disease, symptomatic improvement might be achieved. Control of coronary vasomotor tone and proliferation processes within the vessel wall are both determined by the redox equilibrium of nitric oxide (NO) and superoxide radicals (O2-), induced by angiotensin II. Thus, vasomotor control and vessel wall proliferation is closely related to each other. Aim of a therapeutic intervention to enhance NO bioactivity is either to increase NO production in the endothelium or to decrease O2- production, which rapidly inactivates NO. NO bioactivity can be ameliorated by ACE-inhibitors, increase of shear stress on the endothelium by physical exercise, estrogens or L-arginine. For these therapies clinically an improvement of endothelial vasodilator function could be shown. In addition, improvement of endothelial vasodilator function can be achieved by a treatment which reduced oxidative stress in the vascular wall such as antioxidants and, especially, lipid lowering drugs. Endothelin-antagonists and angiotensin II receptor-blockers are promising to improve endothelial dysfunction. However, these therapies have to be validated. Most therapy strategies, which have shown to ameliorate endothelial dysfunction, are also able to improve prognosis of the patients. Whether endothelial dysfunction alone--without evidence of overt coronary atherosclerosis--is sufficient to justify a long-term therapy to improve prognosis, still has to be clarified.

show abstract

Endotheline bei kardiovaskulären Erkrankungen (Endothelins in cardiovascular disease)

Cited by 3 publications

References 0 publications

Snake Venom Components as Therapeutic Drugs in Ischemic Heart Disease

Snake Venom Components as Therapeutic Drugs in Ischemic Heart Disease

Coronary Artery Disease and Endothelial Function

Therapeutische Optionen zur Verbesserung der Myokardperfusion bei koronarer Atherosklerose

Contact Info

Product

Resources

About